Compare SCCO & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCCO | REGN |
|---|---|---|
| Founded | 1952 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0B | 73.9B |
| IPO Year | N/A | 1991 |
| Metric | SCCO | REGN |
|---|---|---|
| Price | $144.25 | $751.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 23 |
| Target Price | $120.59 | ★ $795.74 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 10-28-2025 | 02-03-2026 |
| Dividend Yield | ★ 2.51% | 0.47% |
| EPS Growth | ★ 25.54 | 2.88 |
| EPS | 4.67 | ★ 41.59 |
| Revenue | $12,334,600,000.00 | ★ $14,247,800,000.00 |
| Revenue This Year | $12.82 | $1.95 |
| Revenue Next Year | $4.89 | $5.47 |
| P/E Ratio | $30.46 | ★ $17.82 |
| Revenue Growth | ★ 12.70 | 2.89 |
| 52 Week Low | $72.75 | $476.49 |
| 52 Week High | $149.75 | $790.98 |
| Indicator | SCCO | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.28 | 60.96 |
| Support Level | $141.84 | $689.88 |
| Resistance Level | $149.75 | $753.61 |
| Average True Range (ATR) | 3.73 | 20.54 |
| MACD | 1.00 | -4.36 |
| Stochastic Oscillator | 75.38 | 60.95 |
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. It generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. The company's geographical segments are The Americas, Europe, and Asia.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).